CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,260,589 | +66.8% | 3,640,235 | +1.1% | 0.02% | +83.3% |
| Q2 2023 | $64,902,849 | +11.2% | 3,601,712 | -0.9% | 0.01% | 0.0% |
| Q1 2023 | $58,386,547 | +13.8% | 3,635,526 | +29.6% | 0.01% | +20.0% |
| Q4 2022 | $51,322,076 | -0.8% | 2,804,485 | +6.5% | 0.01% | -9.1% |
| Q3 2022 | $51,713,000 | +52.1% | 2,633,011 | +44.4% | 0.01% | +57.1% |
| Q2 2022 | $34,010,000 | +50.5% | 1,823,598 | +77.2% | 0.01% | +75.0% |
| Q1 2022 | $22,595,000 | -25.7% | 1,029,364 | -3.8% | 0.00% | -20.0% |
| Q4 2021 | $30,407,000 | +58.2% | 1,070,272 | +17.2% | 0.01% | +66.7% |
| Q3 2021 | $19,220,000 | +36.8% | 913,071 | +22.5% | 0.00% | +50.0% |
| Q2 2021 | $14,051,000 | +66.5% | 745,387 | +35.0% | 0.00% | +100.0% |
| Q1 2021 | $8,437,000 | +7.4% | 552,167 | -0.8% | 0.00% | 0.0% |
| Q4 2020 | $7,854,000 | +14.5% | 556,635 | +27.2% | 0.00% | 0.0% |
| Q3 2020 | $6,860,000 | +25.8% | 437,756 | +40.6% | 0.00% | 0.0% |
| Q2 2020 | $5,453,000 | – | 311,281 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |